Role of lentinan combined with AdIRF3 inhibiting breast cancer growth through enhancing IFN-β secretion
10.7501/j.issn.0253-2670.2019.05.018
- Author:
Chang SU
1
Author Information
1. Department of Oncology, First Teaching Hospital of Tianjin University of TCM
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Immunotherapy;
Interferon;
IRF3;
Lentinan
- From:
Chinese Traditional and Herbal Drugs
2019;50(5):1145-1150
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of lentinan (LNT) combined with IRF3 expressing adenovirus vector on the anti-tumor therapy, and its underlying mechanism. Methods Balb/c bearing TUBO mice were treated with PBS, AdGFP, AdIRF3, LNT, and LNT combined with AdIRF3 to observe the tumor growth curve of mice. qPCR was used to detect the IFN-β level of tumor tissues. ELISPOT was to check the IFN-γ secretion of spleen cells. FACS was used to make sure the percentage of tumor infiltrated T cells. Balb/c-nu mice were inoculated with TUBO cells, and tumor growth was monitored. Anti-IFNAR1 antibody was injected to Babl/c bearing mice, and tumor growth was measured. Results Compared with control groups, LNT combined with AdIRF3 can inhibit the tumor growth and increase the IFN-γ secretion of TUBO-bearing mice. There was no significant difference of the percentage of tumor infiltrated Treg among groups, but the tumor infiltrated CD8+T was significantly higher in LNT combined with AdIRF3 treated mice group. There was no significant difference of tumor growth between Balb-nu mice inoculated with TUBO cells treated by LNT/AdIRF3 and PBS/AdGFP group. The tumor growth was not inhibited in Babl/c bearing mice injected with anti-IFNAR1 antibody and treated by LNT/AdIRF3. Conclusion LNT combined with AdIRF3 can inhibit the tumor growth by activating the IRF3-IFN signaling pathway.
